Replies to post #225210 on Biotech Values

[iwfal]

FGEN

Anemia is not your biggest problem at this stage (GFR<15), is it?

It is *a* problem. But, yeah, probably not your only big problem (e.g. see CHF, or acidosis or ...)

Anyway, am I wrong in now concluding that roxa's MACE benefit is right where you would expect (hope) it to be? Prior to kidney failure (15 < eGFR < 60) and also during incident dialysis.

As I noted in the original post, and on twitter, I am agnostic on this. My prediction is about the split, not the absolute values of either GFR>15 or GFR<15. E.g. Maybe for GFR>15 the MACE/MACE+ HR is 1.05, still nominally worse than 1.0, but much better than 1.25 for GFR<15?

Oh, and one more comment - I'd be surprised if MACE/MACE+ HR was "stat sig superior" in GFR>15. They probably have too few events in the GFR>15 group.